Eiger BioPharmaceuticals2018-03-13T10:47:27+00:00

IN THE NEWS

Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection

October 17th, 2018|

Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection Lambda Antiviral Activity Demonstrated in HDV Infection Currently Dosing Lambda in Combination with Lonafarnib in HDV Infection PALO ALTO, Calif., October 17, 2018 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced positive data with Pegylated Interferon Lambda (Lambda) in the Phase 2 LIMT HDV (Lambda Interferon MonoTherapy in Hepatitis Delta Virus) Study.  LIMT HDV enrolled a total [...]

Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint

October 16th, 2018|

Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint PALO ALTO, Calif., October 16, 2018 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced Phase 2 ULTRA study results in primary and secondary lymphedema of the lower limb demonstrated no improvement of ubenimex over placebo in the primary endpoint of skin thickness and secondary endpoints of limb volume [...]

Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)

October 16th, 2018|

Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH) Primary and Secondary Endpoints Achieved with Statistical SignificanceAvexitide Treatment Reduces Hypoglycemia and Hyperinsulinism PALO ALTO, Calif., October 16, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced positive results from the Phase 2 PREVENT study.  PREVENT is a multi-center, placebo-controlled study investigating the safety and durability of effect of 28-day dosing [...]